212 related articles for article (PubMed ID: 26945455)
1. Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery.
Xu CF; Zhang HB; Sun CY; Liu Y; Shen S; Yang XZ; Zhu YH; Wang J
Biomaterials; 2016 May; 88():48-59. PubMed ID: 26945455
[TBL] [Abstract][Full Text] [Related]
2. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase 2-responsive micelle for siRNA delivery.
Wang HX; Yang XZ; Sun CY; Mao CQ; Zhu YH; Wang J
Biomaterials; 2014 Aug; 35(26):7622-34. PubMed ID: 24929619
[TBL] [Abstract][Full Text] [Related]
4. Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
Yi Y; Kim HJ; Zheng M; Mi P; Naito M; Kim BS; Min HS; Hayashi K; Perche F; Toh K; Liu X; Mochida Y; Kinoh H; Cabral H; Miyata K; Kataoka K
J Control Release; 2019 Feb; 295():268-277. PubMed ID: 30639386
[TBL] [Abstract][Full Text] [Related]
5. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
6. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
[TBL] [Abstract][Full Text] [Related]
7. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery.
Yang XZ; Du JZ; Dou S; Mao CQ; Long HY; Wang J
ACS Nano; 2012 Jan; 6(1):771-81. PubMed ID: 22136582
[TBL] [Abstract][Full Text] [Related]
8. One-pot synthesis of pH-responsive hybrid nanogel particles for the intracellular delivery of small interfering RNA.
Khaled SZ; Cevenini A; Yazdi IK; Parodi A; Evangelopoulos M; Corbo C; Scaria S; Hu Y; Haddix SG; Corradetti B; Salvatore F; Tasciotti E
Biomaterials; 2016 May; 87():57-68. PubMed ID: 26901429
[TBL] [Abstract][Full Text] [Related]
9. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery.
Rahme K; Guo J; Holmes JD; O'Driscoll CM
Colloids Surf B Biointerfaces; 2015 Nov; 135():604-612. PubMed ID: 26322474
[TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
12. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA.
Han L; Tang C; Yin C
Biomaterials; 2015 Aug; 60():42-52. PubMed ID: 25982552
[TBL] [Abstract][Full Text] [Related]
13. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.
Svenson S; Case RI; Cole RO; Hwang J; Kabir SR; Lazarus D; Lim Soo P; Ng PS; Peters C; Shum P; Sweryda-Krawiec B; Tripathi S; van der Poll D; Eliasof S
Mol Pharm; 2016 Mar; 13(3):737-47. PubMed ID: 26835715
[TBL] [Abstract][Full Text] [Related]
14. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization.
Cun D; Jensen DK; Maltesen MJ; Bunker M; Whiteside P; Scurr D; Foged C; Nielsen HM
Eur J Pharm Biopharm; 2011 Jan; 77(1):26-35. PubMed ID: 21093589
[TBL] [Abstract][Full Text] [Related]
15. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
16. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
17. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
18. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.
Jackson MA; Werfel TA; Curvino EJ; Yu F; Kavanaugh TE; Sarett SM; Dockery MD; Kilchrist KV; Jackson AN; Giorgio TD; Duvall CL
ACS Nano; 2017 Jun; 11(6):5680-5696. PubMed ID: 28548843
[TBL] [Abstract][Full Text] [Related]
19. pH-responsive release of proteins from biocompatible and biodegradable reverse polymer micelles.
Koyamatsu Y; Hirano T; Kakizawa Y; Okano F; Takarada T; Maeda M
J Control Release; 2014 Jan; 173():89-95. PubMed ID: 24200745
[TBL] [Abstract][Full Text] [Related]
20. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness.
Ishihara T; Kubota T; Choi T; Takahashi M; Ayano E; Kanazawa H; Higaki M
Int J Pharm; 2009 Jun; 375(1-2):148-54. PubMed ID: 19481700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
